Status:

COMPLETED

Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis

Lead Sponsor:

AstraZeneca

Conditions:

Bronchiectasis

Lung Disease

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to investigate the effect of AZD5069 in patients with bronchiectasis.

Eligibility Criteria

Inclusion

  • Male, or female of non-child bearing potential; ie, women who are permanently or surgically sterilised or post-menopausal.
  • Aged 18 to 80 years inclusive at screening (Visit 1)
  • Have a clinical diagnosis of idiopathic or post infective bronchiectasis as diagnosed with a historical high resolution computerised tomography (HRCT) or bronchogram
  • Be sputum producers with a history of chronic expectoration on most days of most weeks of the year. Patients should have a history of spontaneously producing sputum on a daily basis and should be able to provide at least 2 of the 3 required baseline sputum samples with an average of 3 mL or more.
  • Be on a stable treatment regimen, as judged by the investigator.

Exclusion

  • Any clinically significant disease or disorder
  • Patients with other latent or chronic infections or at risk of infection within 90 days before Visit 2
  • An acute exacerbation or acute respiratory infection (upper or lower) requiring oral steroids or antibiotics within 30 days prior to Visit 2
  • An FEV1 of \<30% of predicted normal at Visit 1
  • Patients who have received live or live-attenuated vaccine in the 2 weeks prior to dosing (Visit 2)
  • Concomitant diagnosis of significant pulmonary disease other than bronchiectasis or COPD, including symptomatic asthma and allergic bronchopulmonary aspergillosis
  • Bronchiectasis associated with a generalised immunodeficiency disorder, where manifestations other than bronchiectasis predominate

Key Trial Info

Start Date :

February 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2012

Estimated Enrollment :

83 Patients enrolled

Trial Details

Trial ID

NCT01255592

Start Date

February 1 2011

End Date

February 1 2012

Last Update

October 8 2015

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

Research Site

Ostrava, Czechia

2

Research Site

Prague, Czechia

3

Research Site

Krakow, Poland

4

Research Site

Lodz, Poland